"This marks the 38th consecutive year in which BD has increased our dividend, reflecting the Company's sustained strong performance and cash flow," said Edward J. Ludwig, BD Chairman and Chief Executive Officer. "We are pleased to be able to continue to create value for our shareholders while also making strategic investments for BD's future."
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
Contact: | |
Colleen T. White, Corporate Communications 201-847-5369 | |
Zachary Nagle, Investor Relations 201-847-5453 | |
SOURCE BD (Becton, Dickinson and Company)